摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,4-二(丁-3-烯-1-基)-6-乙氧基-1,3-二噁烷 | 14689-97-5

中文名称
2,4-二(丁-3-烯-1-基)-6-乙氧基-1,3-二噁烷
中文别名
——
英文名称
1,1-di(2-chloroethoxy)ethane
英文别名
Acetaldehyd-bis-(2-chlorethyl)-acetal;1,1-Bis(2-chloroethoxy)ethane
2,4-二(丁-3-烯-1-基)-6-乙氧基-1,3-二噁烷化学式
CAS
14689-97-5
化学式
C6H12Cl2O2
mdl
——
分子量
187.066
InChiKey
KHNOWHUSVXGGLG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    267.64°C (rough estimate)
  • 密度:
    1.1737

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    10
  • 可旋转键数:
    6
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    18.5
  • 氢给体数:
    0
  • 氢受体数:
    2

SDS

SDS:d9cef0c8657b915bc45ff1e58d141bb8
查看

反应信息

点击查看最新优质反应信息

文献信息

  • NANOPARTICLES CONTAINING AZOLIUM AND N-HETEROCYCLIC CARBENE COMPOUNDS AND USE THEREOF
    申请人:National Dong Hwa University
    公开号:US20170129907A1
    公开(公告)日:2017-05-11
    The present application provides a composition comprising a core formed by gold nanoparticle, a compound of Formula (I): wherein dashed lines in Formula (I) represent (i) with or without an attachment of benzol group, (ii) a delocalized bond where shown within a ring; R 1 is hydrogen or a halogen; R 2 is a linker selected from C 6-20 alkyl or polyethylene glycol; R 3 is C 1-20 alkyl, C 1-20 substituted alkyl, hexadecanyl amido, pyridinyl, benzyl or pyrimidinyl; and a compound of Formula (II): wherein dashed lines, R 1 , R 2 and R 3 are defined as in Formula (II), and M is a metal. The composition has an inhibition ability against a cancer.
    本申请提供了一种组合物,包括由金纳米颗粒形成的核心,以及化合物Formula(I):其中Formula(I)中的虚线表示(i)带有或不带有苯基的附加物,(ii)在环中显示的共轭键;R1是氢或卤素;R2是选择自C6-20烷基或聚乙二醇的连接剂;R3是C1-20烷基,C1-20取代烷基,十六烷基酰胺基,吡啶基,苄基或嘧啶基;以及Formula(II)的化合物:其中虚线,R1,R2和R3如Formula(II)中定义,M是金属。该组合物具有抑制癌症的能力。
  • [EN] COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE LA DYSTROPHIE MYOTONIQUE
    申请人:UNI DE VALÈNCIA
    公开号:WO2016075285A1
    公开(公告)日:2016-05-19
    The present invention relates to a compound of formula (I), provided that this compound is not caffeine, for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising the compound of formula (I). The present invention further relates to new compounds which are dimers of compounds of formula (I).
    本发明涉及一种式(I)的化合物,前提是该化合物不是咖啡因,用于治疗肌张力性疾病类型1和类型2。本发明还涉及包含该式(I)化合物的组合物。本发明还涉及新的化合物,这些化合物是式(I)化合物的二聚体。
  • SEPARATION OF HYDROGEN SULFIDE FROM NATURAL GAS
    申请人:Kortunov Pavel
    公开号:US20150027056A1
    公开(公告)日:2015-01-29
    A process for increasing the selectivity of an alkanolamine absorption process for selectively removing hydrogen sulfide (H 2 S) from a gas mixture which also contains carbon dioxide (CO 2 ) and possibly other acidic gases such as COS, HCN, CS 2 and sulfur derivatives of C 1 to C 4 hydrocarbons, comprises contacting the gas mixture with a liquid absorbent which is a severely sterically hindered capped alkanolamine. The improvement in selectivity is achieved at the high(er) pressures, typically least about 10 bara at conditions nearing the H 2 S/CO 2 equilibrium at which CO 2 begins to displace absorbed hydrosulfide species from the absorbent solution.
    一种增加烷基醇胺吸收过程的选择性的方法,以有选择地从气体混合物中去除硫化氢(H2S),该混合物还包含二氧化碳(CO2)和可能包含其他酸性气体,如COS、HCN、CS2和C1至C4烃的硫衍生物,包括将气体混合物与一种液体吸收剂接触,该吸收剂是一种严重的立体位阻末端烷基醇胺。在高压下(通常至少约10 bara)的改进选择性是在接近H2S / CO2平衡的条件下实现的,此时CO2开始从吸收剂溶液中置换吸收的硫化氢物种。
  • NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF
    申请人:FUJIWARA Hideyasu
    公开号:US20130116430A1
    公开(公告)日:2013-05-09
    An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl group, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R 3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R 4 and R 5 each independently represent a hydrogen atom; and R 2 and R 4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.
    本发明的目的是提供一种具有优异的Syk抑制活性的化合物和制药组合物。本发明提供了一种由以下式(I)表示的烟酰胺衍生物(其中R1表示卤素原子;R2表示C1-12烷基、C2-12烯基、C2-12炔基、C3-8环烷基、芳基、芳基-C1-6烷基或杂环基,每种均可选地具有至少一个取代基;R3表示芳基或杂环基,每种均可选地具有至少一个取代基;R4和R5各自独立地表示氢原子;且R2和R4可以与它们结合的氮原子一起形成具有至少一个取代基的环状氨基团)或其盐,并且用于治疗Syk相关疾病的制药组合物包括该烟酰胺衍生物或其盐。
  • Process for preparing cationic surface active agents
    申请人:TOHO CHEMICAL INDUSTRY CO., LTD.
    公开号:EP0053389A1
    公开(公告)日:1982-06-09
    A process for preparing specific cationic surface active agents in which nitrogen atoms are attached to both ends of a long-chain alkylene group or polyoxyalkylene group having at least 6-24 carbon atoms in the molecule, at least one of said nitrogen atoms constituting a quaternary ammonium structure, and also at least one hydroxyphenethyl group is bonded to at least one of the two nitrogen atoms. These cationic surface active agents can serve as an accelerator which catalytically promotes changes in a chemical and/or physical change process involving a hydrolyzing, deacidizing or extracting operation using an aqueous solution of an alkaline metal hydroxide or an alkaline earth metal hydroxide.
    一种制备特定阳离子表面活性剂的工艺,其中氮原子连接到分子中至少有 6-24 个碳原子的长链烷基或聚氧亚烷基的两端,所述氮原子中至少有一个构成季铵结构,并且至少有一个羟基苯乙基键合到两个氮原子中的至少一个上。这些阳离子表面活性剂可以作为一种促进剂,在涉及使用碱金属氢氧化物或碱土金属氢氧化物水溶液进行水解、脱酸或萃取操作的化学和/或物理变化过程中催化促进变化。
查看更多